OncBioMune Pharmaceuticals

OverviewSuggest Edit

OncBioMune specializes in innovative cancer research. The Company owns the proprietary rights to a therapeutic cancer vaccine and patent-pending targeted therapies. The Company’s vaccines have been proven to be effective in cancer patients with virtually no toxicity, clearing a major hurdle in immunotherapy and oncology and positioning OncBioMune to deliver a new standard of cancer care. Using tumor antigens to immunize patients, OncBioMune’s vaccines can be used as a stand-alone therapeutic or as an adjunct to today’s or future cancer treatments to boost the immune system to attack cancer cells in relapsed, refractory or simply at-risk patients. The Company's approaches slow tumor cell proliferation, help avoid relapse, overcomes drug resistance and extends progression-free and overall survival. 
TypePublic
Founded2005
HQBaton Rouge, US
Websiteoncbiomune.com

Latest Updates

Employees (est.) (Mar 2019)3
Revenue (FY, 2014)$24 (-99%)
Share Price (Nov 2020)$0.1 (-18%)
Cybersecurity ratingCMore

OncBioMune Pharmaceuticals Office Locations

OncBioMune Pharmaceuticals has an office in Baton Rouge
Baton Rouge, US (HQ)
11441 Industriplex Blvd #190
Show all (1)

OncBioMune Pharmaceuticals Financials and Metrics

OncBioMune Pharmaceuticals Revenue

OncBioMune Pharmaceuticals's revenue was reported to be $24 in FY, 2014
USD

Net income (Q1, 2020)

(5.1m)

EBIT (Q1, 2020)

(324.2k)

Market capitalization (24-Nov-2020)

170.7k

Closing stock price (24-Nov-2020)

0.1

Cash (31-Mar-2020)

2.0k

EV

3.8m
OncBioMune Pharmaceuticals's current market capitalization is $170.7 k.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

781.1k77.9k24.0

Cost of goods sold

219.4k52.4k

Gross profit

561.6k25.6k

Gross profit Margin, %

72%33%
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

133.3k125.7k68.6k52.1k(589.0)66.08.014.4k145.7k118.6k

Cost of goods sold

44.6k32.9k28.2k6.9k1.2k10.6k92.3k53.2k

Gross profit

88.7k92.9k40.4k45.1k(1.2k)(589.0)3.8k53.4k65.4k

Gross profit Margin, %

67%74%59%87%100%26%37%55%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

258.1k512.5k13.0k672.8k1.4k201.021.5k

Accounts Receivable

106.6k50.6k

Prepaid Expenses

17.3k22.6k4.9k19.0k30.1k12.7k215.7k40.7k

Inventories

2.2k
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

198.4k88.7k198.1k65.2k31.4k200.0k56.4k62.5k8.9k38.6k16.9k10.4k4.6k184.6k366.5k12.8k10.6k142.5k111.9k83.6k2.1k2.2k50.3k136.1k2.0k

Accounts Receivable

30.6k56.1k94.1k65.7k40.2k170.0k94.1k93.4k

Prepaid Expenses

13.8k21.2k12.9k14.6k17.3k14.3k21.1k4.7k89.04.5k97.03.7k39.5k76.7k45.3k69.7k75.6k99.6k240.8k17.4k226.2k203.9k189.7k235.3k27.1k

Inventories

100.4k96.6k52.6k104.6k106.2k
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(952.5k)(315.9k)(757.4k)(990.4k)(2.0m)(20.5m)6.5m(9.4m)

Depreciation and Amortization

88.3k86.5k17.4k274.01.1k3.7k2.3k2.3k

Inventories

15.0k2.2k

Accounts Payable

68.5k(158.8k)1.3k(23.1k)111.3k164.6k172.1k69.7k
USDQ2, 2012

Debt/Equity

1.5 x

Debt/Assets

0.4 x

Financial Leverage

3.4 x
Show all financial metrics

OncBioMune Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

OncBioMune Pharmaceuticals Online and Social Media Presence

Embed Graph

OncBioMune Pharmaceuticals Blogs

OncBioMune Announces Compelling Pre-Clinical Data for its CD71-Targeted Chemotherapy, PGT, in Models of Lung, Pancreatic and Ovarian Cancers

OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic prostate cancer vaccine immunotherapy and a CD71-targeted cancer therapy combining paclitaxel, gallium, and transferrin, o…

OncBioMune Announces Consulting Agreement with CATO Research LLC for Developing PGT, a Protein Drug Complex Targeting CD71 for Refractory Cancers

OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapy, is pleased to announce that it has entered into a consulting agr…

OncBioMune Announces Former Puma Biotechnology Executive and Genentech Veteran Brian Barnett, M.D., as Chief Executive Officer

BATON ROUGE, La., Jan. 09, 2019 (GLOBE NEWSWIRE) — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, today annou…

Site Visit Planned for December 19, 2018 to Initiate Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer

BATON ROUGE, La., Dec. 07, 2018 — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is pleased to provide an upd…

2018 Global Summit on Genitourinary Malignancies Presentation

2018 Global Summit on Genitourinary Malignancies

OncBioMune Phase 2 Clinical Trial to Begin Enrollment; Company Announces Other Development and Corporate Milestones

BATON ROUGE, La., Oct. 31, 2018 — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, today provides an update on …
Show more

OncBioMune Pharmaceuticals Frequently Asked Questions

  • When was OncBioMune Pharmaceuticals founded?

    OncBioMune Pharmaceuticals was founded in 2005.

  • How many employees does OncBioMune Pharmaceuticals have?

    OncBioMune Pharmaceuticals has 3 employees.

  • Who are OncBioMune Pharmaceuticals competitors?

    Competitors of OncBioMune Pharmaceuticals include Olema Oncology, Northwest Biotherapeutics and Merrimack Pharmaceuticals.

  • Where is OncBioMune Pharmaceuticals headquarters?

    OncBioMune Pharmaceuticals headquarters is located at 11441 Industriplex Blvd #190, Baton Rouge.

  • Where are OncBioMune Pharmaceuticals offices?

    OncBioMune Pharmaceuticals has an office in Baton Rouge.

  • How many offices does OncBioMune Pharmaceuticals have?

    OncBioMune Pharmaceuticals has 1 office.